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Two-year impact of single praziquantel treatment on infection 
in the national control programme on schistosomiasis in 
Burkina Faso
Seydou Touré,a Yaobi Zhang,b Elisa Bosqué-Oliva,b Césaire Ky,a Amado Ouedraogo,a Artemis Koukounari,b  
Albis F Gabrielli,c Bertrand Sellin,d Joanne P Webster b & Alan Fenwick b
Objective To evaluate the impact on schistosomiasis of biennial treatment with praziquantel (PZQ) among school-age children in 
Burkina Faso, the first country that achieved full national coverage with treatment of more than 90% of the school-age population.
Methods A cohort of 1727 schoolchildren (6–14 years old) was monitored at yearly intervals through a longitudinal survey. Additional 
groups of schoolchildren were monitored in cross-sectional surveys. Parasitological examinations for Schistosoma haematobium and 
Schistosoma mansoni were performed, and prevalence and intensity of infection before and after treatment were analysed.
Findings Data from the longitudinal cohort show that a single round of PZQ treatment significantly reduced prevalence of S. haematobium 
infection by 87% (from 59.6% to 7.7%) and intensity of infection by 92.8% (from 94.2 to 6.8 eggs/10 ml of urine) 2 years post-
treatment. The impact on infection was also confirmed by a cross-sectional survey 2 years post-treatment. Importantly, the proportion 
of school-age children with heavy S. haematobium infection decreased from around 25% before treatment to around 2–3% 2 years 
post-treatment. Cross-sectional comparison of S. haematobium infection in 7-year-old children in their first year at school, who received 
treatment through community-based drug delivery, also showed significant reduction in both prevalence (65.9%) and intensity of 
S. haematobium infection (78.4%) 2 years after single treatment. A significant reduction in S. mansoni infection was also achieved.
Conclusion Significant and sustained reduction in S. haematobium infection was achieved by biennial treatment in school-age 
children in Burkina Faso. This may provide a cost-effective treatment strategy for similar national schistosomiasis control programmes 
in sub-Saharan Africa.
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Introduction
Two main forms of human schistosomi-
asis or bilharzia exist in Africa – urinary 
schistosomiasis caused by Schistosoma 
haematobium infection and intestinal 
schistosomiasis caused by Schistosoma 
mansoni infection. There are around 
165 million people in sub-Saharan 
Africa with the disease: about 112 
million with urinary schistosomiasis 
and about 54 million with intestinal 
schistosomiasis.1–3 The mainstay of 
the current strategy recommended by 
WHO against schistosomiasis is mor-
bidity control through preventive che-
motherapy with praziquantel (PZQ).4,5 
Schistosome morbidity is mainly caused 
by eggs trapped in various parts of the 
human body, depending on the species 
of schistosomes, hence the fundamental 
aim of morbidity control is to reduce in-
tensity of infection by drug treatment. 
Several national control programmes 
on schistosomiasis and soil-transmitted 
helminthiasis (STH) are now being 
implemented across sub-Saharan Africa 
with financial and technical support 
from the Schistosomiasis Control 
Initiative.6–8 We have previously re-
ported the successful implementation 
of the national control programme on 
intestinal schistosomiasis and STH us-
ing annual treatment strategy through 
school-based drug delivery for school-
children and community-based drug 
delivery for adults at high risk, and 
the great impact achieved on reducing 
morbidity and infection in Uganda in 
eastern Africa.9,10 We now report the 
impact of biennial treatment strategy 
on urinary schistosomiasis through 
both school- and community-based 
drug deliveries for school-age children 
in Burkina Faso in western Africa.
Burkina Faso is a land-locked 
country in western Africa with a total 
population of about 13 million, of 
which approximately 3.65 million are 
school-age children.11 S. haematobium 
is the main species prevalent through-
out the country with focal prevalence of 
up to 100%, while S. mansoni is present 
mainly in the southern and western 
regions.12 Some small-scale control ac-
tivities with treatment had taken place 
in some areas in the past,11,13 but the na-
tional control programme did not start 
until 2004. Full national coverage of 
treatment was achieved in 2005. A total 
of more than 3.3 million school-age 
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children received their first treatment, 
representing 90.8% of the estimated 
school-age population in the country.11 
Our results at one year post-treatment 
showed that treatment significantly 
reduced infection and morbidity by 
S. haematobium.14 The current paper 
presents the parasitological impact of 
a single treatment on schistosomiasis 
2 years after treatment.
Methods
National control programme
Details about the national schistoso-
miasis control programme supported 
by the Schistosomiasis Control Ini-
tiative were described elsewhere.7,11 
The control strategy adopted by the 
Ministry of Health was modified from 
the WHO guidelines and involved 
treatment once every two years to all 
school-age children (5–15 years old).4,5 
Synergistic treatment for STH was also 
given to those who received treatment 
for schistosomiasis. The first treat-
ment with PZQ and albendazole was 
implemented during 2004 and 2005 
in a staggered two-phased campaign. 
Due to the low school enrolment rate 
in Burkina Faso, treatment was carried 
out both through schools and com-
munities targeting school-age children 
not attending school. As described 
previously,11 the treatment campaign 
was coordinated and supervised by 
the Ministry of Health staff, involving 
education authorities and local com-
munities. A specific national ‘treatment 
week’ was designated in October each 
year and health personnel at each level 
(regional, district and dispensary) were 
mobilized. Drug delivery in schools was 
carried out by trained school teachers. 
To reach non-enrolled children, health 
workers and community drug distribu-
tors formed fixed units at dispensary 
and mobile units that visited villages 
or hamlets seeking school-age chil-
dren not attending school. Treatment 
against schistosomiasis was delivered 
using the WHO dose pole method 
for PZQ (600 mg tablets).15 A single 
dose of albendazole (400 mg) was used 
against STH.
Monitoring survey design
The monitoring survey was carried 
out among enrolled schoolchildren in 
selected schools due to logistic reasons. 
For the longitudinal surveys, sample 
size calculation and cohort design have 
been described elsewhere.14,16 Briefly, 
overall sample size was calculated with 
an expected reduction of 70% in mean 
intensity for S. haematobium over a 
2-year period using the EpiSchisto 
software tool (available at: http://www.
schoolsandhealth.org). An overall drop-
out rate of 40% over the course of the 
monitoring period was also allowed. 
Sentinel schools were randomly selected 
from all schools in four priority regions 
targeted in 2004. Within each school, 
180 children were selected randomly 
from each of the 7-, 8- and 11-year-
old groups with approximately equal 
numbers of boys and girls in each age 
group. However, due to number and 
gender restrictions in each age group 
in each school, the actual age range 
was expanded to 6–14 years. Where 
the total number was not met in one 
school, the closest school with the same 
ecological conditions was selected. As a 
result, a cohort of 1727 schoolchildren 
was randomly selected at baseline from 
16 schools. The cohort children were 
examined at baseline and followed 
up 1 year post-treatment (in 2005) 
and 2 years post-treatment (in 2006). 
At each follow-up, additional seven-
year-old first-year new students (ap-
proximately 10 boys and 10 girls) from 
each sentinel school were randomly 
selected and examined. These children 
were expected to have been targeted 
for treatment through the community-
based drug delivery before they joined 
the schools. Infection status in these 
children should represent the quality 
of community-based treatment.
In addition to the cohort follow-up, 
a cross-sectional survey was conducted 
during the second follow-up (2 years 
post-treatment), in which a group of 
children (7–14 years old) outside the 
original cohort were randomly selected 
and examined in the sentinel schools. 
The number, age and sex structures were 
matched to those in the cohort who 
were present at the second follow-up 
in each school. Infection status in these 
children should represent the quality of 
treatment in children outside cohorts 
in schools, to confirm and validate the 
cohort data, i.e. no preferred treatment 
was given to cohort children.
Parasitic infection status of each 
child was determined by parasitological 
examinations. Crosschecking was car-
ried out for quality control. Monitor-
ing activities received ethical clearance 
from the National Health System Local 
Research Ethics Committee of St Mary’s 
Hospital, London, as well as approval 
from the Ministry of Health of Burkina 
Faso. Written informed consent was 
obtained from head teachers at each 
school with prior agreements from par-
ents or guardians.
Parasitological diagnosis
Urine examination
One urine specimen was collected from 
each child to determine S. haematobium 
infection using the filtration method 
and microscopy. Generally, specimens 
were collected around noon (between 
approximately 10:00 and 13:00), 10 ml 
of urine was filtered through a nylon 
filter (pore size 12 μm, Millipore, United 
Kingdom) and the number of eggs 
counted under a microscope. For speci-
mens of less than 10 ml, the volumes 
were measured before filtration and the 
number of eggs per 10 ml calculated. 
Intensity of S. haematobium infection 
was expressed as number of eggs per 
10 ml of urine (e/10 ml).
Stool examination
A single stool sample was collected from 
each child. Duplicate Kato–Katz slides 
were prepared from each sample and 
examined on the same day to determine 
S. mansoni infections. Eggs were counted 
and individual intensity of infection was 
expressed as eggs per gram of faeces (epg) 
calculated as the arithmetic mean of 
the two individual slide counts. Due to 
logistical reasons, at the baseline survey, 
only around half of cohort children were 
randomly selected and examined by the 
Kato–Katz method.
Data analysis
Of 1727 schoolchildren recruited at 
baseline, 763 were successfully traced 
and re-examined at both follow-ups 
with three complete sets of longitudinal 
parasitological data on S. haematobium. 
Children who dropped out or missed 
either of two follow-up surveys were not 
included in the longitudinal analysis. 
Baseline characteristics of children suc-
cessfully followed-up showed that they 
had a lower mean age (9.6 years versus 
11.0 years; P < 0.01), a lower propor-
tion of boys (54.1% versus 59.1%; 
P < 0.05), higher S. haematobium 
prevalence (59.9% versus 53.1%; P < 
0.01) but a similar intensity of S. hae-
matobium infection (93.3 e/10 ml versus 
91.2 e/10 ml; P > 0.05), compared with 
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those who had dropped out. Among 
763 children, 322 had valid data entry 
for S. mansoni at all three surveys. These 
longitudinal data, together with cross-
sectional analysis of three sets of data 
from the 7-year-old children and two 
sets of data from the 7–14-year-olds, 
are presented in this paper. Baseline 
data from the original cohort, includ-
ing those who dropped out during the 
follow-ups, served as the baseline data 
in the two cross-sectional analyses. 
Result tables together with 95% con-
fidence intervals (CI) were obtained 
using software SAS version 9.1 (SAS 
Institute, Cary, NC, United States of 
America). Arithmetic mean intensity of 
infections was used in the analysis.17,18 
For longitudinal cohort data the differ-
ences were tested using the McNemar’s 
test for prevalence and the Wilcoxon 
signed rank-sum test for mean intensi-
ties. For cross-sectional analysis the χ² 
test was used to compare differences 
in prevalence and the Kruskal–Wallis 
test to compare differences in mean 
intensities.
Table 1.  Schistosoma haematobium prevalence and intensity of infection in the longitudinal cohort children before and after 
treatmenta
Variable Baseline
(95% CI)
1 year 
post-treatment
(95% CI)
2 years 
post-treatment
(95% CI)
Overall  
reduction in %
Prevalence in %
Overall prevalence (n=763) 59.6 (56.2–63.1) 6.2 (4.5–7.9) 7.7 (5.8–9.6) 87.1
By region
Boucle du Mouhoun (n = 238) 48.3 (42.0–54.7) 8.4 (4.9–11.9) 12.2 (8.0–16.3) 74.7
Nord (n = 259) 53.7 (47.6–59.7) 0.8 (0.0–1.8) 2.3 (0.5–4.1) 95.7
Sahel (n = 199) 89.4 (85.2–93.7) 12.1 (7.5–16.6) 11.6 (7.1–16.0) 87.0
Sud Ouest (n = 67) 34.3 (23.0–45.7) 1.5 (0.0–4.4) 1.5 (0.0–4.4) 95.6
By sex
Boys (n = 403) 64.3 (59.6–68.9) 7.7 (5.1–10.3) 11.4 (8.3–14.5)b 82.3
Girls (n = 360) 54.4 (49.3–59.6) 4.4 (2.3–6.6) 3.6 (1.7–5.6) 93.4
Intensity of infection in e/10 ml
Overall mean (n=763) 94.2 (76.4–111.9) 1.0 (0.2–1.9) 6.8 (1.6–12.0)b 92.8
By region
Boucle du Mouhoun (n = 238) 76.4 (52.9–100.0) 0.7 (0.2–1.3) 19.2 (2.7–35.6)b 74.9
Nord (n = 259) 63.4 (38.7–88.2) 0.0 (0.0–0.1) 0.8 (0.0–1.7) 98.7
Sahel (n = 199) 167.7 (117.9–217.4) 3.0 (0.0–6.1) 2.0 (0.5–3.5) 98.8
Sud Ouest (n = 67) 57.7 (11.5–103.9) 0.1 (0.0–0.1) 0.1 (0.0–0.3) 99.8
By sex
Boys (n = 403) 115.9 (91.0–140.8) 1.6 (0.1–3.20) 12.1 (2.4–21.8)b 89.6
Girls (n = 360) 69.9 (44.7–95.1) 0.3 (0.1–0.6) 0.8 (0.0–1.7) 98.9
CI, confidence interval; e/10 ml, number of eggs per 10 ml urine.
a  All data at 1 or 2 years post-treatment were significantly lower than at baseline (all P < 0.01).
b  P < 0.05, significantly higher when compared with 1 year post-treatment.
Results
S. haematobium infection
Longitudinal cohort data
Table 1 summarizes the parasitologi-
cal results from 763 cohort children 
successfully examined at baseline, 
1 year post-treatment and 2 years 
post-treatment. One round of mass 
PZQ treatment significantly reduced 
prevalence in the cohort children from 
59.6% at baseline to 6.2% at 1 year 
post-treatment and, importantly, re-
mained at 7.7% 2 years post-treatment, 
an overall 87.1% reduction over 2 years 
(P < 0.01). The overall intensity of in-
fection was significantly reduced from 
94.2 e/10 ml at baseline to only 1.0 
e/10 ml at 1 year post-treatment and 
6.8 e/10 ml at 2 years post-treatment, 
an overall reduction of 92.8% over 
2 years (P < 0.01). Significant reduc-
tion in both prevalence and intensity of 
infection was found in all four regions 
and in both boys and girls (P < 0.01; 
Table 1). Importantly, before treatment 
the proportion of heavy infections 
(≥ 50 e/10 ml) accounted for over 25% 
of the schoolchildren examined (Fig. 1). 
This decreased to just 0.4% at 1 year 
post-treatment and remained below 2% 
at 2 years post-treatment.
Cross-sectional data
These data were compared with those 
of baseline children with the same ages 
(7–14 years old) in the original cohort 
before treatment. Two years after treat-
ment, overall prevalence and intensity 
of S. haematobium infection were sig-
nificantly lower than those at baseline 
by 77.4% and 80.3% respectively (P < 
0.01). Significant reduction in both 
prevalence and intensity of infection 
was shown in all four regions and in 
both boys and girls (P < 0.01; Table 2). 
As in the cohort data, the proportion of 
heavy infections was reduced from 25% 
to just 3.2% (Fig. 2). However, these 
children outside the cohort did show a 
slightly higher prevalence and intensity 
of S. haematobium infection than those 
in the cohort as in Table 1 (P < 0.01) at 
2 years post-treatment.
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Fig. 1. Changes in the category of intensity of Schistosoma haematobium infection in 
schoolchildren (n=763): 3-year longitudinal data
e/10 ml, number of eggs per 10 ml urine.
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Comparison of 3-year data from the 
7-year-old schoolchildren
Only S. haematobium infection is pre-
sented here, as the infection level for 
other helminths was low. As in Table 3 
(available at: http://www.who.int/
bulletin/volumes/86/10/07-048694/
en/index.html), similar to the cohort 
data, 1 year after treatment overall 
both prevalence and intensity of S. hae-
matobium infection in the 7-year-old 
children showed a dramatic reduction, 
by an average of 82.9% and 92.3% 
respectively (P < 0.01). There was a 
significant uptrend in both overall 
prevalence and intensity of infection 
2 years post-treatment compared with 
1 year post-treatment (P < 0.01), but 
the overall level of prevalence and 
intensity of infection was still far 
below the original level by 65.9% and 
78.4% respectively (P < 0.01). More 
importantly, the proportion of heavy 
infections (≥ 50 e/10 ml) remained 
lower at 2.5% 2 years later compared 
with 14% before treatment (Fig. 3). 
The trend in different regions and in 
both genders was generally similar with 
prevalence and intensity of infection 
post-treatment being significantly lower 
than at baseline (P <  0.01) except in the 
south-west (Sud Ouest) region. There, 
the boys showed a significant increase in 
both prevalence and intensity of infec-
tion 2 years post-treatment compared 
to one year post-treatment, while girls 
did not.
Fig. 2. Changes in the category of intensity of Schistosoma haematobium infection 
in schoolchildren: cross-sectional data 2 years post-treatment (n=761) 
compared with baseline data (n=1644)
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e/10 ml, number of eggs per 10 ml urine; N/A, not available.
S. mansoni infection
Longitudinal cohort data
Parasitological results on S. mansoni 
infection in the longitudinal cohort 
children successfully examined at base-
line and followed-up one year and two 
years post-treatment are summarized in 
Table 4 (available at: http://www.who.
int/bulletin/volumes/86/10/07-048694/
en/index.html). S. mansoni infection 
was detected only in the Sud Ouest re-
gion in sentinel schools with prevalence 
of 13.6% and intensity of infection of 
22.4 epg in the region. Two years after 
treatment these were significantly re-
duced to 1.5% and 2.9 epg respectively 
(P < 0.05).
Cross-sectional data
In the cross-sectional data, S. mansoni 
infection was also shown only in the 
Sud Ouest region. In baseline children 
(7–14 years old) in the original cohort in 
this region, prevalence of S. mansoni in-
fection was 14.2% (95% CI: 10.8–17.6; 
n = 408) and intensity of infection was 
23.0 epg (95% CI: 11.8–34.2; n = 
408) before treatment. Two years after 
treatment, S. mansoni prevalence in this 
region was 7.6% (95% CI: 4.4–11.0; 
n = 248) and intensity of infection was 
16.5 epg (95% CI: 1.9–31.0; n = 248) 
(both P < 0.05).
Discussion
In line with previous findings,12 S. hae-
matobium infection was found preva-
lent throughout cohort schools in 
the country with very high levels of 
infection in the north, particularly in 
the Sahel region where infection was 
nearly universal in some schools (de-
tails not shown), and a moderate level 
of infection in the Sud Ouest region. 
Although S. haematobium infection was 
relatively low in the Sud Ouest com-
pared with other regions, S. mansoni 
infection was also found to be prevalent. 
Therefore, the combined prevalence of 
schistosomiasis was actually very high, 
reaching nearly 50% in the longitudinal 
data and more than 30% in the cross-
sectional data at baseline. The baseline 
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Table 2. Cross-sectional analysis of Schistosoma haematobium infection in the 
7–14-year-old schoolchildren before and after treatment
Variable Baseline
(95% CI)
2 years  
post-treatment
(95% CI)
Overall 
reduction 
in %
Prevalence in %
Overall prevalence 55.8 (53.4–58.2)
(n = 1644)
12.6 (10.2–15.0)
(n = 761)
77.4
By region
Boucle du Mouhoun 58.6 (53.8–63.3)
(n  = 413)
15.8 (11.7–20.0)
(n = 297)
73.0
Nord 61.2 (56.5–65.8)
(n = 417)
2.0 (0.0–4.8)
(n = 99)
96.7
Sahel 84.2 (80.7–87.7)
(n = 412)
30.0 (21.8–38.2)
(n = 120)
64.4
Sud Ouest 18.4 (14.6–22.2)
(n = 402)
4.5 (1.9–7.1)
(n = 245)
75.5
By sex
Boys 59.8 (56.7–63.0)
(n = 936)
16.5 (12.9–20.1)
(n = 406)
72.4
Girls 50.6 (46.9–54.2)
(n = 708)
8.2 (5.3–11.0)
(n = 355)
83.8
Intensity of infection in e/10 ml
Overall mean 91.3 (80.0–102.7)
(n = 1644)
18.0 (9.4–26.6)
(n = 761)
80.3
By region
Boucle du Mouhoun 106.7 (86.0–127.5)
(n = 413)
37.4 (16.9–58.0)
(n = 297)
64.9
Nord 91.0 (67.3–114.6)
(n = 417)
0.1 (0.0–0.2)
(n = 99)
99.9
Sahel 126.9 (99.3–154.4)
(n = 412)
14.5 (0.0–31.2)
(n = 120)
88.6
Sud Ouest 39.4 (22.8–56.1)
(n = 402)
3.4 (0.0–7.3)
(n = 245)
91.4
By sex
Boys 111.8 (95.6–128.1)
(n = 936)
26.8 (12.3–41.3)
(n = 406)
76.0
Girls 64.2 (49.1–79.3)
(n = 708)
7.9 (0.0–15.8)
(n = 355)
87.7
CI, confidence interval; e/10 ml, number of eggs per 10 ml urine; n, sample size in the group.
data confirmed the significant burden 
caused by schistosomiasis to school-age 
children in Burkina Faso. We also found 
universally low STH infections (data 
not shown). This may be due to the fact 
that the national control programme on 
lymphatic filariasis using albendazole 
and ivermectin started in 2001, and 
several rounds of treatment had already 
been implemented in some areas of the 
country.19,20
Impact of treatment
A single treatment significantly reduced 
S. haematobium infection in the country 
and kept it low for the following 2 years. 
Two years after treatment, prevalence 
of S. haematobium infection in school-
age children was still at a significantly 
lower level than at baseline and, more 
importantly, intensity of infection 
remained at a low level. The propor-
tion of heavy infections was greatly 
reduced. This is particularly important 
as high intensity of S. haematobium 
infection has been shown to contribute 
to morbidity, including anaemia, in 
children.14 The reduction in prevalence 
and intensity of infection was confirmed 
by both longitudinal cohort follow-up 
and cross-sectional survey. In previous 
small-scale studies on S. haematobium 
control in eastern Africa, an annual 
treatment strategy was predominantly 
used, with varying results.21,22 However, 
in western Africa, one study in the Niger 
showed that, 3 years after a single PZQ 
treatment, prevalence and intensity of 
S. haematobium infection remained sig-
nificantly lower than at baseline.23,24 In 
another study in Ghana, with one single 
PZQ treatment, intensity of S. haemato-
bium infection was reduced by 80–99% 
12 months after treatment and remained 
very low in two of three study areas 24 
months after treatment.25 Our results 
are in line with these studies, suggesting 
that a more spaced treatment strategy, as 
implemented in Burkina Faso, is highly 
effective on S. haematobium infections, 
even in highly-endemic areas. In ad-
dition, we also observed a significant 
reduction in S. mansoni infection during 
the 2 years after treatment.
One of the factors likely to have 
contributed to the great impact dem-
onstrated in Burkina Faso is the high 
nationwide treatment coverage (over 
90%) achieved in a relatively short space 
of time by the control programme.11 
Another factor is that 2004 was a very 
dry year and treatment was delivered in 
the dry season. These two important 
factors together may have helped to 
reduce transmission26 and, therefore, 
should be considered when implement-
ing a national control programme in 
other sub-Saharan countries to maxi-
mize the treatment impact. Neverthe-
less, the general uptrend of the preva-
lence and intensity of S. haematobium 
infection shown 2 years post-treatment, 
compared with 1 year post-treatment, 
could also signal a potential rebound 
of S. haematobium infection should 
drug distribution be interrupted. This 
therefore highlights the importance of 
continued effort in monitoring disease 
transmission and of repeated treatment 
when and where necessary.
Throughout the 2 years, the drop-
out rate of cohort children was high, 
particularly in the Sud Ouest region 
where very few original cohort children 
were traced and re-examined at both 
follow-ups. One of the main reasons for 
the loss of cohort children was family 
migration, which is very common in the 
country and particularly in this region 
(Seydou Touré, personal observation). 
Another of the main reasons was that a 
proportion of the original cohort (older 
age groups) had naturally progressed to 
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Résumé
Impact à deux ans d’un traitement unique par le praziquantel sur l’infestation par des schistosomiale dans le 
cadre du programme national de lutte contre la schistosomiase du Burkina Faso
Objectif Evaluer l’impact sur la schistosomiase du traitement biennal 
contre la schistosomiase par le praziquantel (PZQ) chez les enfants 
d’âge scolaire du Burkina Faso, premier pays ayant obtenu une 
couverture nationale totale par ce traitement de plus de 90 % de 
la population d’âge scolaire.
Méthodes Une cohorte de 1727 écoliers (6-14 ans) a été suivie à 
intervalles d’un an, à travers une enquête longitudinale. D’autres 
groupes d’écoliers ont été suivis dans le cadre d’enquêtes 
transversales. Des examens parasitologiques, visant à mettre en 
évidence Schistosoma haematobium et Schistosoma mansoni, ont 
été pratiqués. La prévalence et l’intensité de l’infestation avant et 
après le traitement ont également été analysées.
secondary schools over the study period. 
High drop-out is indeed a relatively 
common problem in the monitoring 
activities of our programmes in sub-
Saharan Africa.
Treatment strategy
Unlike in Uganda,9,10 a biennial treat-
ment of school-age children (5–15 
years old) through school-based and 
community-based drug deliveries was 
implemented in Burkina Faso. This 
decision was based on previous experi-
ence with S. haematobium in western 
Africa23–25 and on the fact that the 
ongoing monitoring and evaluation 
activities showed a low level of infection 
1 year post-treatment.14 Current results, 
together with previous findings by oth-
ers,23–25 suggest that the WHO-recom-
mended treatment strategies on urinary 
schistosomiasis should be adopted with 
some degree of flexibility according to 
different epidemiological and geographi-
cal settings. Provided that coverage is 
high and is implemented in a dry season, 
treatment once every two years may 
be sufficient, even in highly-endemic 
regions such as Sahel and Boucle du 
Mouhoun, and in less endemic regions 
perhaps treatment every three or more 
years could equally prove sufficient. It 
is however more difficult to make infer-
ences on the appropriate interval of treat-
ment on intestinal schistosomiasis from 
the current data because of the relatively 
small number of individuals with such 
infection enrolled in our survey, and the 
lower levels of infection registered. Our 
study also suggests that monitoring and 
evaluation is a crucial component of the 
national control programme for fine-
tuning a treatment strategy according 
to national and local epidemiological 
conditions.
Previous analysis has shown that in 
Burkina Faso, the total costs per child 
treated against schistosomiasis and 
STH, including drug and delivery, was 
Fig. 3. Changes in the category of intensity of Schistosoma haematobium infection in 
the 7-year-old first-year schoolchildren before treatment (n=154), 1 year post-
treatment (n=307) and 2 years post-treatment (n=317) 
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US$ 0.32.11 A possible further reduc-
tion of treatment frequency for urinary 
schistosomiasis, where applicable, is 
expected to further reduce the overall 
costs of the control activities. The 
current national control programme 
in Burkina Faso has recently entered 
a new phase – integrated control of 
neglected tropical diseases.27,28 The 
next rounds of treatment are planned 
to be delivered in an integrated man-
ner to include schistosomiasis, STH, 
lymphatic filariasis, onchocerciasis 
and trachoma.5 In this framework, the 
best way to tackle schistosomiasis is 
being assessed. Treatment with reduced 
frequency plus integrated control 
strategies may significantly increase 
the sustainability of national control 
programmes in Burkina Faso and in 
the rest of sub-Saharan Africa.
Conclusion
This study showed that a significant 
impact on urinary schistosomiasis 
was achieved by biennial distribution 
of PZQ with high coverage rates in 
Burkina Faso. We demonstrated, for the 
first time on a national scale, that such 
treatment frequency can be successfully 
applied to control urinary schistoso-
miasis in sub-Saharan Africa. This may 
provide a cost-effective treatment strat-
egy for similar national schistosomiasis 
control programmes in resource-limited 
settings.  ■
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Resumen
Impacto en la esquistosomiasis al cabo de dos años de un solo tratamiento con prazicuantel en el programa 
nacional contra esa infección en Burkina Faso
Objetivo Evaluar el impacto en la esquistosomiasis a los dos años 
del tratamiento bienal con prazicuantel (PZQ) en una población de 
niños en edad escolar en Burkina Faso, el primer país que logró la 
plena cobertura nacional tratando a más del 90% de la población 
en edad escolar.
Métodos Se realizó un estudio longitudinal para seguir la 
evolución de una cohorte de 1727 escolares (6-14 años) a 
intervalos de un año. Se sometió también a seguimiento a otros 
grupos de escolares mediante encuestas transversales. Se 
realizaron exámenes parasitológicos para detectar la presencia 
de Schistosoma haematobium y Schistosoma mansoni, 
determinándose la prevalencia e intensidad de la infección antes y 
después del tratamiento.
Resultados Los datos de la cohorte longitudinal muestran que, 
transcurridos dos años, una sola ronda de tratamiento con PZQ 
había reducido considerablemente la prevalencia -un 87% (de 
59,6% a 7,7%)- e intensidad -92,8% (de 94,2 a 6,8 huevos/10 
ml de orina)- de la infección por S. haematobium. El impacto en la 
infección se vio confirmado también por una encuesta transversal 
realizada a los 2 años del tratamiento. Un dato importante es que la 
proporción de niños en edad escolar con infección seria disminuyó 
de aproximadamente un 25% antes del tratamiento a un 2%-3% 
a los 2 años del mismo. La comparación transversal del estado de 
infección por S. haematobium entre niños de 7 años en su primer 
año de escolaridad, que recibieron tratamiento gracias a un sistema 
de suministro de medicamentos basado en la comunidad, también 
puso de relieve una reducción importante tanto de la prevalencia 
(65,9%) como de la intensidad (78,4%) de la infección por 
S. haematobium dos años después del tratamiento único. También 
se logró reducir de forma notable la infección por S. mansoni.
Conclusión El tratamiento bienal de los niños en edad escolar en 
Burkina Faso logró reducir considerablemente y de forma sostenida 
la infección por S. haematobium. Esto brindaría una estrategia de 
tratamiento costoeficaz para otros programas nacionales similares 
de control de la esquistosomiasis en el África subsahariana.
Résultats Les données collectées pour la cohorte longitudinale 
montrent qu’une tournée unique de traitement par le PZQ a permis 
de réduire la prévalence de l’infestation par S. haematobium 
de 87 % (baisse considérable de 59,6 % à 7,7 %) et l’intensité 
de cette infestation de 92,8 % (baisse de 94,2 à 6,8 œufs/10 ml 
d’urine) deux ans après le traitement. Cet effet sur l’infestation a 
été confirmé par une enquête transversale réalisée 2 ans également 
après le traitement. Point important : la proportion d’enfants d’âge 
scolaire lourdement infestés par S. haematobium est tombée de 
près de 25 % avant le traitement à environ  2-3 % deux ans après 
celui-ci. Des comparaisons transversales chez les enfants de 7 ans 
en première année d’école primaire, ayant reçu le traitement par 
le biais des systèmes de délivrance communautaires, ont mis en 
évidence une diminution à la fois de la prévalence (65,9 %) et de 
l’intensité (78,4 %) de l’infestation par S. haematobium deux ans 
après le traitement unique. Ces comparaisons relevaient aussi une 
baisse conséquente de l’infestation par S. mansoni.
Conclusion Une diminution importante et durable de l’infestation 
par S. haematobium a été obtenue par un traitement biennal des 
enfants d’âge scolaire au Burkina Faso. Cette démarche pourrait 
constituer une stratégie de traitement d’un bon rapport coût/
efficacité pour d’autres programmes nationaux analogues de lutte 
contre la schistosomiase en Afrique sub-saharienne.
صخلم
وساف انيكروب في ةحفاكملل ينطولا جمانبرلا لظ في تايسراهلبلا ءادب ىودعلا لىع ينماع ةدلم هدحو ليتناوكيزابرلاب ةجلاعلما يرثأت
 ةدلم ايسراهلبلاب ينباصلما سرادلما نس في لافطلأا ةجلاعم يرثأت مييقت :ضرغلا
 ةيطغتلا زرحي دلب لوأ وهو ،وساف انيكروب في ليتناوكيزابرلا مادختساب ينماع
.سرادلما نس في لافطلأا نم %90 لىع وبري ام ةجلاعبم ةلماكلا ةينطولا
 سرادلما نس في لافطلأا نم 1727 اهماوق ةيبارتأ ةعومجم ْتَدُِصر :ةقيرطلا
 ْتَدََصرو .نيلاوط حسم للاخ نم ةيونس تاترف لىع )ًاماع 14 – 6 رماعأب(
 متو  .سرادلما  لافطأ  نم  ًةيفاضإ  ٍتاعومجم  تاعاطقلا  ُةددعتم  ٌتاحوسم
 تايسراهلبلاو  ةيومدلا  تايسراهلبلا  فشكل  تايليفطلل  تارابتخا  ءارجإ
.اهدعبو ةجلاعلما لبق اهتدشو ىودعلا راشتنا ل َّدعم ليلحتو ،ةينوسنلما
 نأ  ةينلاوطلا  ةيبارتلأا  ةعومجلماب  ةصاخلا  تايطعلما  ترهظأ  :تادوجولما
 راشتنا  ل َّدعم  تصَّلَق  دق  ليتناوكيزابرلا  مادختساب  ةجلاعملل  ةدحاو  ةرود
 تضفخو ،)%7.7 لىإ %59.6 نم( %87 وحنب ةيومدلا ايسراهلبلاب ةباصلإا
 ضيم دعب )لوبلا نم لم 10/ةضيب 6.8 لىإ 94.2 نم( %92.8 وحنب اهتدش
 ددعتلما  حسلما  للاخ نم ةباصلإا  لىع يرثأتلا  دكأت  ماك .ةجلاعلما  نم ينماع
 نس في لافطلأا ةبسن نأ ،انمهي امو .ةجلاعلما نم ينماع ضيم دعب تاعاطقلا
 %25 نم تضفخنا ،ةيومدلا ةيسراهلبلاب ةليقثلا ىودعلاب ينباصلما سرادلما
 ترهظأ ماك .ةجلاعلما نم ينماع ضيم دعب %3 – 2 وحن لىإ ةجلاعلما لبق
 تايسراهلبلاب  ةعباسلا  نس  في  لافطلأا  ةباصلإ  تاعاطقلا  ةددعتلما  ةنراقلما
 ءاتيلإا للاخ نم ةجلاعلما اوقلت نيذلاو ،سرادلما في مهل ماع لوأ في ةيومدلا
 ةدشو )%65.9( راشتنلاا لدعم نم ٍّلك في ًايربك ًاضافخنا ،ةيودلأل يعمتجلما
 ةجلاعلما  لىع ينماع  ضيم دعب  )%78.4(  ةيومدلا  ايسراهلبلا  ءادب  ىودعلا
 ءادب ىودعلا لدعم في ٌيربك ٌضافخنا  ًاضيأ َزِرُْحأ ماك .هدحو ليتناوكيزابرلاب
.ةينوسنلما تايسراهلبلا
 ًايربك ًاضافخنا ينماع ةدلم سرادلما نس في لافطلأا ُةجلاعم تزرحأ :جاتنتسلاا
 حرطي دقو .وساف انيكروب في ةيومدلا تايسراهلبلاب ةباصلإا لدعم في ًارمتسمو
 ةلثمالما ةينطولا جمابرلل فيلاكتلا ءاقل ةلاعف ةجلاعم ةيجيتاترسا زاجنلإا اذه
.ةيقيرفلأا ءارحصلا بونج ةعقاولا نادلبلا في تايسراهلبلا ءاد ةحفاكلم
Research
Schistosomiasis treatment in Burkina Faso
787Bulletin of the World Health Organization | October 2008, 86 (10)
Seydou Touré et al.
References
Chitsulo L, Engels D, Montresor A, Savioli L. The global status of 1. 
schistosomiasis and its control. Acta Trop 2000;77:41-51. PMID:10996119 
doi:10.1016/S0001-706X(00)00122-4
van2.  der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, 
Habbema JD, et al. Quantification of clinical morbidity associated with 
schistosome infection in sub-Saharan Africa. Acta Trop 2003;86:125-39. 
PMID:12745133 doi:10.1016/S0001-706X(03)00029-9
Steinmann3.  P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water 
resources development: systematic review, meta-analysis, and estimates 
of people at risk. Lancet Infect Dis 2006;6:411-25. PMID:16790382 
doi:10.1016/S1473-3099(06)70521-7
Prevention4.  and control of schistosomiasis and soil-transmitted helminthiasis. 
Report of a WHO expert committee. Geneva: WHO; 2002 (WHO Technical 
Report Series No. 912). pp. 1-57.
Preventive5.  chemotherapy in human helminthiasis. Geneva: WHO; 2006.
Fenwick6.  A. New initiatives against Africa’s worms. Trans R Soc Trop Med Hyg 
2006;100:200-7. PMID:16343572 doi:10.1016/j.trstmh.2005.03.014
Garba7.  A, Toure S, Dembele R, Bosque-Oliva E, Fenwick A. Implementation of 
national schistosomiasis control programmes in West Africa. Trends Parasitol 
2006;22:322-6. PMID:16690357 doi:10.1016/j.pt.2006.04.007
Kabatereine8.  NB, Fleming FM, Nyandindi U, Mwanza JC, Blair L. The control of 
schistosomiasis and soil-transmitted helminths in East Africa. Trends Parasitol 
2006;22:332-9. PMID:16713357 doi:10.1016/j.pt.2006.05.001
Kabatereine9.  NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, 
Fleming FM, et al. Impact of a national helminth control programme on 
infection and morbidity in Ugandan schoolchildren. Bull World Health Organ 
2007;85:91-9. PMID:17308729 doi:10.2471/BLT.06.030353
Zhang10.  Y, Koukounari A, Kabatereine N, Fleming F, Kazibwe F, Tukahebwa E,  
et al. Parasitological impact of two-year preventive chemotherapy on 
schistosomiasis and soil-transmitted helminthiasis in Uganda. BMC Med 
2007;5:27. PMID:17767713 doi:10.1186/1741-7015-5-27
Gabrielli11.  AF, Toure S, Sellin B, Sellin E, Ky C, Ouedraogo H, et al. A combined 
school- and community-based campaign targeting all school-age children 
of Burkina Faso against schistosomiasis and soil-transmitted helminthiasis: 
performance, financial costs and implications for sustainability. Acta Trop 
2006;99:234-42. PMID:16997268 doi:10.1016/j.actatropica.2006.08.008
Poda12.  JN, Traore A, Sondo BK. Schistosomiasis endemic in Burkina Faso. Bull 
Soc Pathol Exot 2004;97:47-52. PMID:15104159
Sellin13.  B, Simonkovich E, Sellin E, Rey JL, Mouchet F. Course of urinary 
schistosomiasis over 3 consecutive years after treatment with metrifonate 
in a dry savanna village in Upper Volta. Med Trop (Mars) 1984;44:357-9. 
PMID:6542966
Koukounari A, Gabrielli AF, Touré S, Bosqué-Oliva E, Zhang Y, Sellin B, et al.  14. 
Schistosoma haematobium infection and morbidity before and after 
large-scale administration of praziquantel in Burkina Faso. J Infect Dis 
2007;196:659-69. PMID:17674306 doi:10.1086/520515
Montresor15.  A, Engels D, Chitsulo L, Bundy DAP, Brooker S, Savioli L. 
Development and validation of a “tablet pole” for the administration 
of praziquantel in sub-Saharan Africa. Trans R Soc Trop Med Hyg 
2001;95:542-4. PMID:11706670 doi:10.1016/S0035-9203(01)90034-3
Brooker16.  S, Whawell S, Kabatereine NB, Fenwick A, Anderson RM. Evaluating 
the epidemiological impact of national control programs for helminths. Trends 
Parasitol 2004;20:537-45. PMID:15471706 doi:10.1016/j.pt.2004.08.012
Fulford17.  AJ. Dispersion and bias: can we trust geometric means? 
Parasitol Today 1994;10:446-8. PMID:15275533 doi:10.1016/0169-
4758(94)90181-3
Montresor18.  A. Arithmetic or geometric means of eggs per gram are not 
appropriate indicators to estimate the impact of control measures in helminth 
infections. Trans R Soc Trop Med Hyg 2007;101:773-6. PMID:17544470 
doi:10.1016/j.trstmh.2007.04.008
Molyneux19.  DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug 
treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 
2003;19:516-22. PMID:14580963 doi:10.1016/j.pt.2003.09.004
Burkina20.  Faso. Global Alliance to Eliminate Lymphatic Filariasis. Available from: 
http://www.filariasis.org/resources/burkina_faso.htm [accessed on 20 August 
2008].
Magnussen P. Treatment and re-treatment strategies for schistosomiasis 21. 
control in different epidemiological settings: a review of 10 years’ 
experiences. Acta Trop 2003;86:243-54. PMID:12745141 doi:10.1016/
S0001-706X(03)00045-7
Satayathum22.  SA, Muchiri EM, Ouma JH, Whalen CC, King CH. Factors 
affecting infection or reinfection with Schistosoma haematobium in coastal 
Kenya: survival analysis during a nine-year, school-based treatment program. 
Am J Trop Med Hyg 2006;75:83-92. PMID:16837713
Campagne23.  G, Garba A, Barkire H, Vera C, Sidiki A, Chippaux JP. Continued 
ultrasonic follow-up of children infected with Schistosoma haematobium 
after treatment with praziquantel. Trop Med Int Health 2001;6:24-30. 
PMID:11263461 doi:10.1046/j.1365-3156.2001.00660.x
Garba24.  A, Campagne G, Tassie JM, Barkire A, Vera C, Sellin B, et al. Long-term 
impact of a mass treatment by praziquantel on morbidity due to Schistosoma 
haematobium in two hyperendemic villages of Niger. Bull Soc Pathol Exot 
2004;97:7-11. PMID:15104149
Nsowah25. -Nuamah NN, Aryeetey ME, Jolayemi ET, Wagatsuma Y, Mensah G, 
Dontwi IK, et al. Predicting the timing of second praziquantel treatment and  
its effect on reduction of egg counts in southern Ghana. Acta Trop 
2004;90:263-70. PMID:15099813 doi:10.1016/j.actatropica.2002.03.001
Gurarie26.  D, King CH. Heterogeneous model of schistosomiasis transmission 
and long-term control: the combined influence of spatial variation and 
age-dependent factors on optimal allocation of drug therapy. Parasitology 
2005;130:49-65. PMID:15700757 doi:10.1017/S0031182004006341
Molyneux27.  DH, Hotez PJ, Fenwick A. “Rapid-impact interventions”: how a 
policy of integrated control for Africa’s neglected tropical diseases could 
benefit the poor. PLoS Med 2005;2:e336. PMID:16212468 doi:10.1371/
journal.pmed.0020336
Hotez28.  PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. 
Control of neglected tropical diseases. N Engl J Med 2007;357:1018-27. 
PMID:17804846 doi:10.1056/NEJMra064142
Research
Schistosomiasis treatment in Burkina Faso
ABulletin of the World Health Organization | October 2008, 86 (10)
Seydou Touré et al.
Table 3. Cross-sectional analysis of Schistosoma haematobium infection in the 7-year-old first-year schoolchildren before and after 
treatmenta
Variable Baseline
(95% CI)
1 year post-treatment
(95% CI)
2 years post-treatment
(95% CI)
Overall 
reduction in %
Prevalence in %
Overall prevalence 41.6 (33.8–49.3)
(n = 154)
7.1 (4.3–10.1)
(n = 307)
14.2 (10.4–18.0)
(n = 317)b
65.9
By region
Boucle du Mouhoun 35.6 (23.4–47.8)
(n = 59)
0 (N/A)
(n = 20)
6.7 (0.4–13.0)
(n = 60)
81.2
Nord 51.4 (35.3–67.5)
(n = 37)
4.0 (0.2–7.9)
(n = 99)
2.0 (0.0–4.8)
(n = 98)
96.1
Sahel 92.0 (81.4–100.0)
(n = 25)
16.7 (9.6–23.7)
(n = 108)
30.0 (21.8–38.2)
(n = 120)b
67.4
Sud Ouest 0 (N/A)
(n = 33)
0 (N/A)
(n = 80)
7.7 (0.0–16.1)
(n = 39)
–
By sex
Boys 39.8 (29.2–50.3)
(n = 83)
6.0 (2.2–9.8)
(n = 150)
18.4 (12.5–24.4)
(n = 163)b
53.8
Girls 43.7 (32.1–55.2)
(n = 71)
8.3 (4.0–12.6)
(n = 157)
9.7 (5.1–14.4)
(n = 154)
77.8
Intensity of infection in e/10 ml
Overall mean 63.5 (30.0–97.0)
(n = 154)
4.9 (0.0–11.4)
(n = 307)
13.7 (2.5–24.8)
(n = 317)b
78.4
By region
Boucle du Mouhoun 63.7 (22.2–105.3)
(n = 59)
0 (N/A)
(n = 20)
33.6 (0.0–80.3)
(n = 60)
47.3
Nord 44.0 (0.0–100.5)
(n = 37)
1.1 (0.0–2.7)
(n = 99)
0.1 (0.0–0.2)
(n = 98)
99.8
Sahel 175.6 (10.9–340.2)
(n = 25)
13.0 (0.0–31.5)
(n = 108)
14.5 (0.0–31.3)
(n = 120)b
91.7
Sud Ouest 0 (N/A)
(n = 33)
0 (N/A)
(n = 80)
14.5 (0.0–38.5)
(n = 39)
–
By sex
Boys 91.2 (33.4–148.9)
(n = 83)
1.0 (0.0–2.1)
(n = 150)
24.9 (3.3–46.6)
(n = 163)b
72.7
Girls 31.2 (4.1–58.2)
(n = 71)
8.7 (0.0–21.4)
(n = 157)
1.7 (0.5–3.0)
(n = 154)
94.6
CI, confidence interval; e/10 ml, number of eggs per 10 ml urine; N/A, not available; n, sample size in the group.
a  Except in Sud Ouest, all data at 1 year or 2 years post-treatment were significantly lower than at baseline (all P < 0.01). 
b  P < 0.05, significantly higher when compared with 1 year post-treatment.
Table 4. Schistosoma mansoni prevalence and intensity of infection in the longitudinal cohort children before and after treatmenta
Variable Baseline
(95% CI)
1 year post-treatment
(95% CI)
2 years post-treatment
(95% CI)
Prevalence in %
Overall (n = 322) 2.8 (1.0–4.6) 1.6 (0.2–2.9) 0.3 (0.0–0.9)
Sud Ouest (n = 66) 13.6 (5.4–21.9) 7.6 (1.2–14.0) 1.5 (0.0–4.5)
Intensity of infection in epg
Overall (n = 322) 4.6 (0.0–9.7) 7.0 (0.0–15.1) 0.6 (0.0–1.8)
Sud Ouest (n = 66) 22.4 (0.0–47.3) 33.8 (0.0–73.7) 2.9 (0.0–8.7)
CI, confidence interval; epg, number of eggs per gram of faeces.
a  All data at 2 years post-treatment were significantly lower than at baseline (all P < 0.05). No significant difference was found between 1 year post-treatment and 
baseline or between 2 years and 1 year post-treatment (P > 0.05).
